Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market

DelveInsight’s “Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) – Market Insights, Epidemiology, and Market Forecast – 2036” report offers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

To know in detail about the PH-ILD market outlook, drug uptake, treatment scenario, and epidemiology trends, click here:https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market Report

• In May 2025, YUTREPIA (treprostinil) inhalation powder received full FDA approval for improving exercise capacity in adults with PAH and PH-ILD, becoming the first dry powder prostacyclin therapy enabled by Liquidia’s PRINT technology, delivering uniform particles to the deep lung via a low-resistance, breath-actuated device.
• In August 2024, Liquidia received tentative FDA approval to market YUTREPIA for the treatment of PAH and PH-ILD, submitted via the 505(b)(2) pathway using nebulized TYVASO as the reference listed drug, with commercialization enabled once regulatory exclusivity expired in May 2025.
• In January 2025, at the 43rd J.P. Morgan Healthcare Conference, Liquidia Corporation presented advancements in treprostinil (L606), highlighting its twice-daily dosing, improved tolerability, and delivery via a next-generation breath-actuated handheld nebulizer, with plans to expand into IPF, PH-COPD, and SSc-RP.
• In May 2025, Gossamer Bio reported completion of enrollment for the ongoing global Phase III PROSERA study evaluating seralutinib in patients with Functional Class II and III PAH.
• In June 2025, Halo Biosciences reported publication of results from its Phase IIa SATURN study in Thorax, marking a pivotal milestone in the development of HB-1614 for PH-ILD.
• In June 2025, Insmed reported positive topline results from its Phase IIb study of TPIP as a once-daily treatment for PAH.
• In September 2024, TREPROST (treprostinil) inhalation solution received approval in Japan for a new indication targeting adults at risk of disease progression.
• According to DelveInsight’s analysis, the PH-ILD market size in the 7MM was valued at approximately USD 3 billion in 2025 and is projected to expand at a CAGR of 3.9% during the forecast period through 2036.
• The United States accounted for the largest PH-ILD market share among the 7MM, with revenue of approximately USD 2,500 million in 2025.
• The total diagnosed prevalent population of PH-ILD across the 7MM was estimated at approximately 182,000 in 2025.
• In the US, diagnosed prevalent cases of PH-ILD reached approximately 83,000 in 2025, with gender-specific analysis showing a slightly higher prevalence in males (~43,000) than females (~40,000).
• In 2025, EU4 and the UK together contributed approximately 70,000 diagnosed prevalent cases of PH-ILD, with the United Kingdom representing the largest individual European segment at nearly 18,000 cases.
• Currently, there are no curative therapies for PH-ILD, and approved inhaled therapies such as treprostinil (YUTREPIA) and treprostinil (TYVASO/TYVASO DPI/TREPROST) remain the anchor of care, with clinicians reporting off-label use of PAH-approved medications in nearly half of PH-ILD patients.
• In 2025, treprostinil (TYVASO/TYVASO DPI/TREPROST) generated over ~USD 1,100 million in the 7MM.
• Key PH-ILD Companies: Liquidia Corporation, United Therapeutics, Pharmosa BioPharm, Halo Biosciences, Roivant Sciences/Pulmovant, Insmed, Gossamer Bio, and others.
• Key PH-ILD Therapies: Treprostinil (YUTREPIA), Treprostinil (TYVASO/TYVASO DPI/TREPROST), Treprostinil liposomal (L606), Treprostinil Palmitil Inhalation Powder (TPIP), Mosliciguat, Seralutinib, H1614 (HB-1614), and others.

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Overview

PH-ILD refers to a wide range of lung conditions involving scarring or inflammation of the interstitium, the thin layer of tissue between the air sacs and nearby blood vessels that maintains the structure of the alveoli and enables oxygen transfer into the bloodstream.

Chronic smoking and long-term exposure to environmental or occupational toxins can damage lung tissue, contributing to inflammation and fibrosis that elevate pulmonary artery pressure.

There is no standardized noninvasive method for diagnosing PH-ILD; assessment relies on pulmonary function tests, the 6-minute walk distance test, echocardiography, and imaging such as chest X-rays or CT scans, while Right Heart Catheterization remains the most accurate and conclusive confirmatory method, since ILD and PH share many overlapping signs that complicate distinguishing between the two.

Get a free sample for the PH-ILD Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Epidemiology

The PH-ILD epidemiology section provides insights into the historical and current PH-ILD patient pool and forecasted trends across the seven major markets (7MM) the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan for the study period 2022–2036.

PH-ILD Epidemiology Segmentation

• Diagnosed Prevalent Cases of ILD
• Type-specific Diagnosed Prevalent Cases of ILD
• Type-specific Diagnosed Prevalent Cases of PH-ILD
• Total Diagnosed Prevalent Cases of PH-ILD
• Gender-specific Diagnosed Prevalent Cases of PH-ILD

Download the report to understand which factors are driving PH-ILD epidemiology trends: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential PH-ILD drugs expected to launch during the forecast period 2026–2036, covering peak performance, factors affecting growth years, patient uptake by therapy, and anticipated sales.

Treprostinil (YUTREPIA), an advanced dry powder inhalation formulation engineered with optimized excipients for precise pulmonary drug deposition, is expected to witness medium-to-fast uptake given its potential to significantly improve patient-friendly disease management.

Next-generation modalities such as treprostinil liposomal (L606) and treprostinil palmitil inhalation powder (TPIP) are expected to see more gradual, sustained adoption as they optimize drug concentration in the lungs and provide more comprehensive disease control.

The report also covers Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Development Activities: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

PH-ILD Marketed and Late-Stage Therapies and Key Companies

Currently, the landscape is anchored by approved inhaled therapies focused on symptom management, with no curative options yet available.

• Treprostinil (YUTREPIA): Liquidia Corporation – dry powder inhalation formulation of treprostinil sodium, a prostacyclin agonist, delivered via a single-use handheld inhaler with excipients including L-leucine, polysorbate 80, sodium chloride, sodium citrate, and trehalose; approved in the US in 2025 for PAH and PH-ILD.
• Treprostinil (TYVASO/TYVASO DPI/TREPROST): United Therapeutics – inhaled prostacyclin agonist approved for PAH and PH-ILD, marketed in the US since 2022 and Japan since 2024.

PH-ILD Emerging Therapies

• Treprostinil liposomal (L606): Pharmosa BioPharm/Liquidia Corporation – Phase III liposomal treprostinil formulation with 110–140 nm particle size, engineered for sustained pulmonary release and prolonged systemic circulation; anticipated US launch 2030.
• Treprostinil Palmitil Inhalation Powder (TPIP): Insmed – late-stage oral inhalation prostacyclin agonist candidate for PH-ILD.
• Mosliciguat: Roivant Sciences/Pulmovant – Phase II inhaled guanylate cyclase stimulant being developed for PH-ILD.
• H1614 (HB-1614): Halo Biosciences – Phase II oral hyaluronan-synthesis inhibitor, with Phase IIa SATURN study results published in Thorax.
• Seralutinib: Gossamer Bio – being evaluated in the global Phase III PROSERA study in Functional Class II and III PAH.

Discover more about therapies set to shape the PH-ILD market share: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market Drivers

• Increasing Disease Recognition and Diagnostic Advancements.
• Progressive Nature of Cardiopulmonary Impairment.
• Emergence of Next-Generation Inhaled and Oral Modalities.
• Persistent Off-Label Prescribing Gap.
• Advancing Diagnostic and Biomarker Research.

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market Barriers

• Diagnostic Challenges and Risk of Misdiagnosis.
• Reliance on Invasive Confirmatory Procedures.
• Scarcity of Specifically Approved Therapies.
• Lack of Standardized Diagnostic Pathways.
• High Treatment Costs.

Scope of the PH-ILD Market Report

• Study Period: 2022–2036
• Forecast Period: 2026–2036
• Coverage: 7MM (United States, EU4 [Germany, France, Italy, and Spain], the United Kingdom, and Japan)
• Key Companies: Liquidia Corporation, United Therapeutics, Pharmosa BioPharm, Halo Biosciences, Roivant Sciences/Pulmovant, Insmed, Gossamer Bio, and other emerging market players.
• Key Therapies: Treprostinil (YUTREPIA), Treprostinil (TYVASO, TYVASO DPI, TREPROST), Treprostinil Liposomal (L606), Treprostinil Palmitil Inhalation Powder (TPIP), Mosliciguat, Seralutinib, H1614 (HB-1614), and other emerging therapies.
• Therapeutic Assessment: Comprehensive analysis of currently marketed and emerging PH-ILD therapies.
• Market Dynamics: Detailed evaluation of market drivers, barriers, opportunities, and challenges.
• Competitive Intelligence Analysis: SWOT analysis, product attribute analysis, cost assumptions and pricing analogues, reimbursement landscape, and competitive benchmarking.
• Additional Coverage: PH-ILD unmet needs, KOL insights, market access strategies, and reimbursement analysis across the 7MM.

Contact Information

Company Name: DelveInsight Business Research LLP

Contact Person: Mehul Malhotra

Email: info@delveinsight.com

Phone: +1 469 945 7679

Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States

Website: DelveInsight Consulting

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.